Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

Dermatology Review

Dermatology Review is a forum which gives the physician an opportunity to view the latest opinions being expressed at international dermatology meetings, in journals and other mediums. This content has been made available through unrestricted educational grants from various SkinCareGuide sponsors.

The following are available on this page:

  • Dermatology Review, February 2005
  • Dermatology Review, September 2004
  • Dermatology Review, July 2004
  • Topical Delivery: A Recently Patented Process Combining Hydrophilic & Hydrophobic Polymers, from Drug Delivery Technology, February 2005
  • Tachyplylaxis And Rebound Effects Do Not Appear To Be Associated With Use Of Fluticasone Propionate (FP)
Dermatology Review, February 2005

  Dermatology Review, February 2005

This issue addresses recent advances in therapeutic options for a variety of skin diseases including atopic dermatitis, psoriasis, and rosacea.

This issue brings you information on Dermatology Update, a leading forum for the sharing and learning about new drugs and exciting new therapeutic approaches in the field of dermatology, which held its 20th meeting October 14-16th, 2004. It combined workshops and plenary sessions led by Canadian dermatologists and international speakers. This issue of Focus on Dermatology brings you some exciting reports from those workshops and introduces you to two new drugs recently approved in Canada, Amevive and Cutivate.

Clinical commentaries for this issue have been supplied by Dr. Lyn Guenther, Dr. Richard Thomas, Dr. Rod Kunynetz, Dr. Jerry Tan, and Dr. Ron Vender.

Dermatology Review, September 2004

  Dermatology Review, September 2004

This issue addresses recent advances in managing recurrent atopic dermatitis.

A variety of therapeutic options are discussed, including azathioprine, loratadine syrup, fexofenadine, cyclosporin, tacrolimus, and a special focus on the efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Available in both English and French.

Clinical commentaries for this issue have been supplied by Dr. Gordon Searles, Dr. Jerry Tan, and Dr. Marni Wiseman.

Dermatology Review, July 2004

  Dermatology Review, July 2004

This first issue addresses recent advances in therapeutic options for a variety of skin diseases including atopic dermatitis, psoriasis, and rosacea.

This issue of Focus on Dermatology brings an interesting mix of treatment options including combined therapies of new or existing drugs, and is available in both English and French.

Clinical commentaries for this first issue have been supplied by Dr. Stuart Maddin, Dr. Jerry Tan, and Dr.Richard Thomas.

A Recently Patented Process Combining Hydrophilic & Hydrophobic Polymers

Topical Delivery:   www.invisicare.com

  A Recently Patented Process Combining Hydrophilic & Hydrophobic Polymers
By James Roszell, PhD, and James W.E. Paterson, PhD.
from Drug Delivery Technology, February 2005, pages 42-47.

The data presented in this article demonstrates the utility of the Invisicare® system by SkinVisible for use as a cosmetic or pharmaceutical delivery system.

Extended skin binding, resistance to wash off, controlled release of active ingredients, and the cosmetic appeal of the Invisicare® system are all discussed, with skin biopsy photos, several graphs, and a table of in vitro permeability to common skin irritants.

  February 2005 issue of Drug Delivery Technology.

Tachyplylaxis And Rebound Effects Do Not Appear To Be Associated With Use Of Fluticasone Propionate (FP)

  Tachyplylaxis And Rebound Effects Do Not Appear To Be Associated With Use Of Fluticasone Propionate (FP)

This study includes background on topical corticosterioids, tachyphylaxis, and rebound effects, with an indepth look at the methods of the study and the Objective SCORAD. The results are displayed in a rich graph documenting the SCORAD from the beginning of the stabilisation phase to the end of the follow-up phase, and includes a conclusion with an interpretation of the SCORAD data.

J. Berth-Jones1, M. Herdman2, E Glazenburg3
on behalf of an International Study Group.
1Coventry, UK,   2GSK, R&D, UK,   3GSK, The Netherlands

  Download the PDF of the poster illustrated and described above.